Hepatab 550 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Rifaximin |
| Company | Ibn sina pharmaceuticals ltd |
| Also available as |
Title
Hepatab
Categories
- Traveler's Diarrhea Treatment
- Hepatic Encephalopathy Risk Reduction
- Irritable Bowel Syndrome Bacterial Overgrowth
Description
Hepatab is a non-systemic antibiotic indicated for the treatment of traveler's diarrhea, reduction in risk of overt hepatic encephalopathy, and bacterial overgrowth of irritable bowel syndrome.
Dosage
Dosage varies depending on the condition being treated. For example, 200mg 3 times daily for 3 days for traveler's diarrhea, 550mg 2 times daily for hepatic encephalopathy, and 400mg-550mg 3 times daily for bacterial overgrowth of irritable bowel syndrome.
Pharmacology
- ModeOfAction: Inhibits bacterial RNA synthesis by action on the beta-subunit of the DNA-dependent RNA polymerase
- BactericidalAction: Exerts bactericidal action against many species of Gram-positive and Gram-negative, aerobic and anaerobic bacteria
Indications
- TravelerDiarrhea: Treatment of traveler's diarrhea by noninvasive strains of E. coli
- HepaticEncephalopathyRiskReduction: Reduction in risk of overt hepatic encephalopathy
- IrritableBowelSyndromeBacterialOvergrowth: Bacterial overgrowth of irritable bowel syndrome
Interaction
In vitro study suggests Hepatab induces CYP3A4, but not expected to induce CYP3A4 in patients with normal liver function
Contraindications
Contraindicated in patients with a hypersensitivity to Rifaximin or to any of the rifamycin antimicrobial agents, or any components of this product
SideEffects
- Flatulence
- Headache
- Abdominal pain
- Rectal tenesmus
- Defecation urgency
- Nausea
- Constipation
- Pyrexia
- Vomiting
- Anaphylaxis
- Angioneurotic edema
- Exfoliative dermatitis
PregnancyAndLactation
Pregnancy category C. It is not known whether Rifaximin is excreted in human milk.
Precautions
Hepatab is not effective in patients with diarrhea complicated by fever and/or blood in the stools. Therapy should be discontinued if diarrhea symptoms worsen or persist for more than 24-48 hours. Pseudomembranous colitis has been reported with nearly all antibacterial agents.
UseInSpecialPopulations
- RenalImpairment: The pharmacokinetics of Hepatab in patients with impaired renal function has not been studied
- HepaticImpairment: Systemic exposure of Hepatab markedly elevated in patients with hepatic impairment compared to healthy subjects
OverdoseEffects
No specific information available on the treatment of overdose with Hepatab. In case of overdose, discontinue Hepatab, treat symptomatically, and institute supportive measures as required
TherapeuticClass
4-Quinolone preparations
StorageConditions
Keep below 30°C temperature, away from light and moisture. Keep out of the reach of children